Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of VARIVAX New Seed Process in Children
NCT02062502Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2014
- Primary completion
- Feb 2015
- Modality
- Prophylactic Vaccines, DNA Vaccines, Live Biotherapeutic Products
01
Overview
A Phase 3 trial of varicella virus vaccine live in varicella (VZV), sponsored by Merck & Co.. Started Mar 2014; status: completed.
02
Drugs
varicella virus vaccine live
03
Conditions
varicella (VZV)
Beyond the preview
Go deeper on NCT02062502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02062502.